The findings from the Lairson, Lawson and Schultz labs point the potential new use of an existing drug.
The new technique from the Barbas lab allows drug developers to forge more stable antibody-drug candidates.
The new study from the Kissil lab showed a drug candidate slowed the proliferation and progression of a specific type of tumor cell.
“Their deep financial and business experience will be invaluable to Scripps as we chart our future course,” says TSRI President and CEO Michael A. Marletta.